LONDON BROKER RATINGS: UBS, RBC and Citi cut easyJet; UBS lowers Mondi
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
| Price | 2,001.00p on 30-06-2026 at 11:20:53 |
|---|---|
| Change | 21.50p 1.09% |
| Buy | 2,001.00p |
| Sell | 2,000.00p |
| Last Trade: | Sell 600.00 at 2,000.4659p |
| Day's Volume: | 3,192,505 |
| Last Close: | 1,979.50p |
| Open: | 1,999.50p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,984.50p - 2,006.00p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £80.17b |
| VWAP: | 1,996.61636p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 600 | 2,000.4659p | Ordinary |
12:20:52 - 30-Jun-26 |
| Unknown* | 0 | 2,001.00p | SI Trade |
12:20:01 - 30-Jun-26 |
| Sell* | 2 | 2,000.00p | SI Trade |
12:20:01 - 30-Jun-26 |
| Unknown* | 0 | 2,000.00p | SI Trade |
12:20:01 - 30-Jun-26 |
| Unknown* | 0 | 2,000.00p | OTC Trade |
12:19:51 - 30-Jun-26 |
| Unknown* | 0 | 2,000.00p | OTC Trade |
12:19:51 - 30-Jun-26 |
| Unknown* | 0 | 2,000.00p | SI Trade |
12:19:23 - 30-Jun-26 |
| Unknown* | 0 | 2,001.00p | SI Trade |
12:19:23 - 30-Jun-26 |
| Unknown* | 0 | 2,001.00p | SI Trade |
12:19:23 - 30-Jun-26 |
| Unknown* | 0 | 2,000.00p | SI Trade |
12:19:07 - 30-Jun-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 29th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 29th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 26th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 24th Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 24th Jun 2026 2:52 pm | RNS | GSK announces tender offer to acquire Nuvalent |
| 23rd Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 22nd Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 17th Jun 2026 4:06 pm | RNS | cUTI oral antibiotic Tebipenem approved by US FDA |
| 15th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 12th Jun 2026 7:00 am | RNS | Momelotinib orphan drug designations for VEXAS |